Literature DB >> 7671109

Regulated high-level human beta-globin gene expression in erythroid cells following recombinant adeno-associated virus-mediated gene transfer.

M P Einerhand1, M Antoniou, S Zolotukhin, N Muzyczka, K I Berns, F Grosveld, D Valerio.   

Abstract

Gene therapy approaches for beta-thalassemia and sickle cell anemia focus on the transfer of a human beta-globin gene into the patient's hematopoietic stem cells (HSC). Expression of the transferred sequences should be erythroid specific and match the expression of the endogenous alpha-globin genes in adult erythropoiesis. Here we explore the potential of recombinant adeno-associated virus (AAV) vectors for human beta-globin gene transfer. We have constructed a recombinant AAV-vector containing a human beta-globin gene together with the DNasel hypersensitive sites 4, 3 and 2 of the human beta-globin locus control region. The vector replicates to high titers and can efficiently transduce hematopoietic and non-hematopoietic cells. In transduced and G418 selected murine erythroleukemia (MEL) cell clones, human beta-globin gene expression was regulated and reached levels comparable to endogenous murine beta maj. These data show that AAV-vectors are promising tools in gene therapy approaches for the haemoglobinopathies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7671109

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  9 in total

Review 1.  Adeno-associated virus vectors and hematology.

Authors:  D W Russell; M A Kay
Journal:  Blood       Date:  1999-08-01       Impact factor: 22.113

2.  Enhanced long-term transduction and multilineage engraftment of human hematopoietic stem cells transduced with tyrosine-modified recombinant adeno-associated virus serotype 2.

Authors:  M Ariel Kauss; Laura J Smith; Li Zhong; Arun Srivastava; K K Wong; Saswati Chatterjee
Journal:  Hum Gene Ther       Date:  2010-09       Impact factor: 5.695

3.  Adeno-associated virus vector integration junctions.

Authors:  E A Rutledge; D W Russell
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Analysis of recombinant adeno-associated virus packaging and requirements for rep and cap gene products.

Authors:  K A Vincent; S T Piraino; S C Wadsworth
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

5.  Recombinant adeno-associated virus mediates a high level of gene transfer but less efficient integration in the K562 human hematopoietic cell line.

Authors:  P Malik; S A McQuiston; X J Yu; K A Pepper; W J Krall; G M Podsakoff; G J Kurtzman; D B Kohn
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

6.  Evaluation of beta-globin gene therapy constructs in single copy transgenic mice.

Authors:  J Ellis; P Pasceri; K C Tan-Un; X Wu; A Harper; P Fraser; F Grosveld
Journal:  Nucleic Acids Res       Date:  1997-03-15       Impact factor: 16.971

7.  Recombinant AAV2 transduction of primitive human hematopoietic stem cells capable of serial engraftment in immune-deficient mice.

Authors:  Leah Santat; Helicia Paz; Christie Wong; Lijing Li; James Macer; Stephen Forman; K K Wong; Saswati Chatterjee
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-25       Impact factor: 11.205

8.  Adeno-associated virus type 2-mediated transduction of murine hematopoietic cells with long-term repopulating ability and sustained expression of a human globin gene in vivo.

Authors:  S Ponnazhagan; M C Yoder; A Srivastava
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

Review 9.  Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting.

Authors:  W Walther; U Stein
Journal:  J Mol Med (Berl)       Date:  1996-07       Impact factor: 4.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.